{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:18:24Z","timestamp":1793085504451,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010679","name":"Pasteur Institute of Iran","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.xphs.2022.12.025","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T11:09:30Z","timestamp":1673003370000},"page":"991-999","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Multi-Epitope Vaccine Candidates Associated with Mannosylated Chitosan and LPS Conjugated Chitosan Nanoparticles Against Brucella Infection"],"prefix":"10.1016","volume":"112","author":[{"given":"Zohre","family":"Sadeghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Fasihi-Ramandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Davoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeid","family":"Bouzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.xphs.2022.12.025_bib0001","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1086\/319235","article-title":"Infectious diseases: considerations for the 21st century","volume":"32","author":"Fauci","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.xphs.2022.12.025_bib0002","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3201\/eid0302.970219","article-title":"Brucellosis: an overview","volume":"3","author":"Corbel","year":"1997","journal-title":"Emerging Infect Dis"},{"issue":"2","key":"10.1016\/j.xphs.2022.12.025_bib0003","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1473-3099(06)70382-6","article-title":"The new global map of human brucellosis","volume":"6","author":"Pappas","year":"2006","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.xphs.2022.12.025_bib0004","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.ajpath.2015.03.003","article-title":"Pathogenesis and immunobiology of brucellosis: review of Brucella\u2013Host Interactions","volume":"185","author":"de Figueiredo","year":"2015","journal-title":"Am J Pathol"},{"key":"10.1016\/j.xphs.2022.12.025_bib0005","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/743509","article-title":"A history of the development of Brucella vaccines","volume":"2013","author":"Avila-Calder\u00f3n","year":"2013","journal-title":"Biomed Res Int"},{"issue":"10","key":"10.1016\/j.xphs.2022.12.025_bib0006","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1128\/IAI.73.10.6537-6546.2005","article-title":"A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response","volume":"73","author":"Cassataro","year":"2005","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.xphs.2022.12.025_bib0007","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13567-015-0199-7","article-title":"Recent advances in Brucella abortus vaccines","volume":"46","author":"Dorneles","year":"2015","journal-title":"Vet Res"},{"issue":"17","key":"10.1016\/j.xphs.2022.12.025_bib0008","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.2217\/nnm.14.187","article-title":"Recent advances in peptide-based subunit nanovaccines","volume":"9","author":"Skwarczynski","year":"2014","journal-title":"Nanomedicine"},{"issue":"3","key":"10.1016\/j.xphs.2022.12.025_bib0009","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4161\/hv.1.3.1851","article-title":"Towards an epitope-based human vaccine for influenza","volume":"1","author":"Ben-Yedidia","year":"2005","journal-title":"Hum Vaccin"},{"issue":"4","key":"10.1016\/j.xphs.2022.12.025_bib0010","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0952-7915(03)00083-9","article-title":"Epitope-based vaccines: an update on epitope identification, vaccine design and delivery","volume":"15","author":"Sette","year":"2003","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"10.1016\/j.xphs.2022.12.025_bib0011","doi-asserted-by":"crossref","first-page":"778","DOI":"10.4161\/hv.27332","article-title":"Recent progress in adjuvant discovery for peptide-based subunit vaccines","volume":"10","author":"Azmi","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.xphs.2022.12.025_bib0012","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1021\/acs.chemrev.9b00472","article-title":"Peptide-based vaccines: current progress and future challenges","volume":"120","author":"Malonis","year":"2019","journal-title":"Chem Rev"},{"issue":"15","key":"10.1016\/j.xphs.2022.12.025_bib0013","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85955","article-title":"Adjuvanted multi-epitope vaccines protect HLA-A* 11: 01 transgenic mice against Toxoplasma gondii","volume":"1","author":"El Bissati","year":"2016","journal-title":"JCI insight"},{"key":"10.1016\/j.xphs.2022.12.025_bib0014","doi-asserted-by":"crossref","first-page":"e6185","DOI":"10.7717\/peerj.6185","article-title":"Application of built-in adjuvants for epitope-based vaccines","volume":"6","author":"Lei","year":"2019","journal-title":"PeerJ"},{"issue":"5","key":"10.1016\/j.xphs.2022.12.025_bib0015","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2174\/1570164617666190919120140","article-title":"Multi-Epitope Vaccines (MEVs), as a novel strategy against infectious diseases","volume":"17","author":"Goumari","year":"2020","journal-title":"Curr Proteomics"},{"key":"10.1016\/j.xphs.2022.12.025_bib0016","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.2147\/IJN.S249942","article-title":"Nanoparticle-based vaccines for brucellosis: calcium phosphate nanoparticles-adsorbed antigens induce cross protective response in mice","volume":"15","author":"Sadeghi","year":"2020","journal-title":"Int J Nanomed"},{"issue":"2","key":"10.1016\/j.xphs.2022.12.025_bib0017","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1586\/ecp.11.5","article-title":"The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system","volume":"4","author":"Engel","year":"2011","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"17","key":"10.1016\/j.xphs.2022.12.025_bib0018","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1016\/j.vaccine.2010.08.002","article-title":"TLR-based immune adjuvants","volume":"29","author":"Steinhagen","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.xphs.2022.12.025_bib0019","first-page":"189","article-title":"Improved immunogenicity of tetanus toxoid by Brucella abortus S19 LPS adjuvant","volume":"11","author":"Mohammadi","year":"2014","journal-title":"Iran J Immunol"},{"issue":"2","key":"10.1016\/j.xphs.2022.12.025_bib0020","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00430-014-0356-z","article-title":"Influence of Brucella abortus lipopolysaccharide as an adjuvant on the immunogenicity of HPV-16 L1VLP vaccine in mice","volume":"204","author":"Kianmehr","year":"2015","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.xphs.2022.12.025_bib0021","series-title":"Lipopolysaccharide: A Tool and Target in Enterobacterial Vaccine Development","author":"Nagy","year":"2008"},{"issue":"2","key":"10.1016\/j.xphs.2022.12.025_bib0022","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3390\/molecules23020229","article-title":"Chemical modification of chitosan for efficient vaccine delivery","volume":"23","author":"Xing","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.xphs.2022.12.025_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2018.08.054","article-title":"Immunomodulatory properties of chitosan polymers","author":"Moran","year":"2018","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.xphs.2022.12.025_bib0024","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1080\/21691401.2017.1290646","article-title":"Vibrio cholerae lipopolysaccharide loaded chitosan nanoparticle could save life by induction of specific immunoglobulin isotype","volume":"46","author":"Fasihi-Ramandi","year":"2018","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"4","key":"10.1016\/j.xphs.2022.12.025_bib0025","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11259-015-9645-2","article-title":"Survey of Omp19 immunogenicity against Brucella abortus and Brucella melitensis: influence of nanoparticulation versus traditional immunization","volume":"39","author":"Abkar","year":"2015","journal-title":"Vet Res Commun"},{"issue":"2","key":"10.1016\/j.xphs.2022.12.025_bib0026","first-page":"97","article-title":"Chitosan-based intranasal vaccine against Escherichia coli O157: H7","volume":"20","author":"Doavi","year":"2016","journal-title":"Iran Biomed J"},{"issue":"9\u201310","key":"10.1016\/j.xphs.2022.12.025_bib0027","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1166\/jnn.2006.434","article-title":"Receptor-mediated gene delivery into antigen presenting cells using mannosylated chitosan\/DNA nanoparticles","volume":"6","author":"Kim","year":"2006","journal-title":"J Nanosci Nanotechnol"},{"key":"10.1016\/j.xphs.2022.12.025_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105829","article-title":"Evaluation of immunogenicity of novel multi-epitope subunit vaccines in combination with poly I: c against Brucella melitensis and Brucella abortus infection","volume":"75","author":"Sadeghi","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.xphs.2022.12.025_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbiotec.2020.01.016","article-title":"Mannosylated chitosan nanoparticles loaded with FliC antigen as a novel vaccine candidate against Brucella melitensis and Brucella abortus infection","author":"Sadeghi","year":"2020","journal-title":"J Biotechnol"},{"issue":"2","key":"10.1016\/j.xphs.2022.12.025_bib0030","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/vaccines4020012","article-title":"Recent advances in subunit vaccine carriers","volume":"4","author":"Vartak","year":"2016","journal-title":"Vaccines"},{"key":"10.1016\/j.xphs.2022.12.025_bib0031","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.3389\/fimmu.2020.583077","article-title":"Emerging concepts and technologies in vaccine development","volume":"11","author":"Brisse","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.xphs.2022.12.025_bib0032","first-page":"1","article-title":"Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health","author":"Fries","year":"2020","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.xphs.2022.12.025_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2021.113172","article-title":"Brucella antigens (BhuA, 7\u03b1-HSDH, FliC) in poly I: c adjuvant as potential vaccine candidates against brucellosis","volume":"500","author":"Sadeghi","year":"2022","journal-title":"J Immunol Methods"},{"issue":"2","key":"10.1016\/j.xphs.2022.12.025_bib0034","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1039\/C5SC03892H","article-title":"Peptide-based synthetic vaccines","volume":"7","author":"Skwarczynski","year":"2016","journal-title":"Chem Sci"},{"issue":"36","key":"10.1016\/j.xphs.2022.12.025_bib0035","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1016\/j.vaccine.2009.05.009","article-title":"Therapeutic efficacy of a multi-epitope vaccine against Helicobacter pylori infection in BALB\/c mice model","volume":"27","author":"Zhou","year":"2009","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.xphs.2022.12.025_bib0036","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1128\/CVI.00066-11","article-title":"Evaluation of a novel chimeric B cell epitope-based vaccine against mastitis induced by either Streptococcus agalactiae or Staphylococcus aureus in mice","volume":"18","author":"Xu","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"10.1016\/j.xphs.2022.12.025_bib0037","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1046\/j.1523-1755.1999.00369.x","article-title":"Th1 and Th2 T helper cell subsets affect patterns of injury and outcomes in glomerulonephritis","volume":"55","author":"Holdsworth","year":"1999","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.xphs.2022.12.025_bib0038","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.cyto.2004.12.009","article-title":"Interferon-\u03b3 associated cytokines and chemokines produced by spleen cells from Brucella-immune mice","volume":"30","author":"Paranavitana","year":"2005","journal-title":"Cytokine"},{"issue":"5","key":"10.1016\/j.xphs.2022.12.025_bib0039","article-title":"Host immune responses to the intracellular bacteria Brucella: does the bacteria instruct the host to facilitate chronic infection?","volume":"26","author":"Baldwin","year":"2006","journal-title":"Critic Rev Immunol"},{"key":"10.1016\/j.xphs.2022.12.025_bib0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev-animal-021815-111326","article-title":"Brucella spp. virulence factors and immunity","volume":"4","author":"Byndloss","year":"2016","journal-title":"Annu Rev Anim Biosci"},{"issue":"31","key":"10.1016\/j.xphs.2022.12.025_bib0041","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1016\/j.vaccine.2015.05.057","article-title":"Immune response triggered by Brucella abortus following infection or vaccination","volume":"33","author":"Dorneles","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.xphs.2022.12.025_bib0042","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.vetmic.2017.05.012","article-title":"Brucella lipopolysaccharide reinforced Salmonella delivering Brucella immunogens protects mice against virulent challenge","volume":"205","author":"Lalsiamthara","year":"2017","journal-title":"Vet Microbiol"},{"issue":"4","key":"10.1016\/j.xphs.2022.12.025_bib0043","doi-asserted-by":"crossref","first-page":"437","DOI":"10.14202\/vetworld.2018.437-445","article-title":"Validation of immunomodulatory effects of lipopolysaccharide through expression profiling of Th1 and Th2 biased genes in Newcastle disease virus vaccinated indigenous chicken","volume":"11","author":"Bhardwaj","year":"2018","journal-title":"Vet World"},{"issue":"23","key":"10.1016\/j.xphs.2022.12.025_bib0044","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.1016\/j.vaccine.2006.03.043","article-title":"Helicobacter pylori lipopolysaccharide promotes a Th1 type immune response in immunized mice","volume":"24","author":"Taylor","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.xphs.2022.12.025_bib0045","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3389\/fcimb.2017.00445","article-title":"Intranasal vaccination with mannosylated chitosan formulated DNA vaccine enables robust IgA and cellular response induction in the lungs of mice and improves protection against pulmonary mycobacterial challenge","volume":"7","author":"Wu","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"issue":"07","key":"10.1016\/j.xphs.2022.12.025_bib0046","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3855\/jidc.6625","article-title":"Host response to Brucella infection: review and future perspective","volume":"9","author":"Elfaki","year":"2015","journal-title":"J Infect Dev Countr"},{"issue":"3","key":"10.1016\/j.xphs.2022.12.025_bib0047","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1574-6976.2010.00211.x","article-title":"Towards a Brucella vaccine for humans","volume":"34","author":"Perkins","year":"2010","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.xphs.2022.12.025_bib0048","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1302561","article-title":"Humoral immunity and CD4+ Th1 cells are both necessary for a fully protective immune response upon secondary infection with Brucella melitensis","author":"Vitry","year":"2014","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.xphs.2022.12.025_bib0049","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/SHK.0000000000000042","article-title":"The immunobiology of TLR4 agonists: from endotoxin tolerance to immunoadjuvants","volume":"40","author":"Bohannon","year":"2013","journal-title":"Shock"},{"key":"10.1016\/j.xphs.2022.12.025_bib0050","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/526391","article-title":"Mannosylated chitosan nanoparticles for delivery of antisense oligonucleotides for macrophage targeting","volume":"2014","author":"Shilakari Asthana","year":"2014","journal-title":"Biomed Res Int"},{"issue":"3","key":"10.1016\/j.xphs.2022.12.025_bib0051","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.biologicals.2014.01.002","article-title":"Immunological evaluation of mannosylated chitosan nanoparticles based foot and mouth disease virus DNA vaccine, pVAC FMDV VP1\u2013OmpA in guinea pigs","volume":"42","author":"Nanda","year":"2014","journal-title":"Biologicals"},{"issue":"7","key":"10.1016\/j.xphs.2022.12.025_bib0052","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1128\/IAI.70.7.3324-3329.2002","article-title":"Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane protein","volume":"70","author":"Bhattacharjee","year":"2002","journal-title":"Infect Immun"},{"issue":"11","key":"10.1016\/j.xphs.2022.12.025_bib0053","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1080\/21645515.2017.1369639","article-title":"A novel immunization approach for dengue infection based on conserved T cell epitopes formulated in calcium phosphate nanoparticles","volume":"13","author":"Huang","year":"2017","journal-title":"Hum Vaccin Immunother"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922006153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922006153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:39:57Z","timestamp":1758361197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354922006153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0022354922006153"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2022.12.025","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-Epitope Vaccine Candidates Associated with Mannosylated Chitosan and LPS Conjugated Chitosan Nanoparticles Against Brucella Infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2022.12.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc. on behalf of American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}